To evaluate the effects of parenteral cefoxitin therapy on human fecal flora, we cultured fecal specimens obtained from six patients before, during, and after therapy and used standard methods to identify and quantify all microorganisms. The maJor changes (observed in at least three patients) included the acquisition or proliferation of group D Streptococcus species, coagulase-negative Staphylococcus species, cefoxitin-resistant members of the family Enterobacteriaceae, Pseudomonas species, and various species of the Bacteroides fragilis group. The most striking finding was ingrowth of Clostridium difficile, noted in five of the six patients. There was concomitant eradication or decrease Qf cefoxidti-susceptible Enterobacteriaceae family members, Bacteroides species other than the B. fragilis group, Clostridium species other than C. difficile, and Lactobacillus species. These marked alterations of fecal flora may have important clinical consequences.
Although it has long been recognized that antimicrobial therapy may produce marked changes in the intestinal flora (2, 12) , it is only in recent years, with the increased recognition of the importance of the flora as a reservoir of potential pathogens and the advent of extremely broadspectrum antibacterial agents, that iatrogenic changes in intestinal microecology have been recognized as having clinical importance.
Cefoxitin is an antimicrobial agent that is active against many facultative bacteria and most clinically significant anaerobic bacteria (10) and is excreted into the intestinal tract in appreciable concentrations (5) . Thus, changes in intestinal microecology might be expected with its use. Because of these considerations, we evaluated the effects of parenteral cefoxitin therapy upon fecal flora.
MATERIALS AND METHODS
Eleven hospitalized, adult male patients with infections for which cefoxitin was judged to be appropriate therapy were chosen to have detailed fecal flora studies performed before, during and after therapy. They had not received antimicrobial agents in the preceding 2 weeks and had no known underlying gastrointestinal disorders. Five patients did not complete the study because they received an antimicrobial agent in addition to cefoxitin or because a fecal specimen after therapy could not be obtained. Patients received cefoxitin at daily doses of from 6 to 12 g, with durations of therapy from 8 to 23 days. All had infections of soft tissue or bone. Written informed consent was obtained from all patients.
Fecal specimens were collected within 1 day before therapy, at 5 to 12 days of therapy, and 1 to 10 days after therapy. Specimens were collected in cardboard or plastic containers and either were placed immediately in an an- (4, 6, 11) . Incubation of plates, enumeration of colonies, and identification of isolates were performed by standard, previously described methods (3, 4, 11) . With these methods, microorganisms present in counts less than 1 log1o per gram are not detectable. Susceptibility of facultative and aerobic isolates to cefoxitin was determined by the disk diffusion method, with susceptibility defined as a zone of inhibition of 18 mm or more in diameter around a 30-,ug disk (11) . For isolates of the Bacteroides fragilis group, susceptibilities were determined by an agar dilution method (11) . Fecal specimens and broth cultures of isolates of Clostridium difficile were assayed in HeLa cell tissue culture for the presence of cytotoxin as previously described (7) . Concentrations of cefoxitin in the feces of two patients were measured with high-pressure liquid chromatography by methods previously described (14) .
Paired t tests (1) were used to evaluate the significance of changes in counts of various organisms, with counts after therapy compared with counts before therapy. For this analysis, counts of all cefoxitin-susceptible, facultative, gram-negative bacilli and all cefoxitin-resistant, facultative and aerobic gram-negative bacilli were summed for each patient before testing. Tables 1 to 4 show results of fecal cultures done before, during, and after cefoxitin therapy. To simplify presentation of data, only the genus is reported for some organisms (although species identification was performed for most isolates).
RESULTS
Total microorganism counts (obtained by counting all colonies present on the anaerobic blood agar plate which contained 30 to 300 colonies [11] ), total counts of facultative and aerobic organisms (estimated by adding counts of all facultative and aerobic isolates), and total counts of an- (Tables 1 and 2) .
However, appreciable changes in certain components of the fecal microftora were noted in three or more patients. An increase in counts of 2 log1o or more of group D Streptococcus sp. occurred in three cases, and acquisition of coagplase-negative Staphylococcus sp. occurred during or after therapy in three patients (Table 1) . It was an unexpected finding that total pounts of the B. fragilis group were unaffected by therapy (Table 2) , because the majority of isolates in this group are reportedly susceptible to cefoxitin. To determine whether resistance to cefoxitin had developed, we retrieved these isolates from storage and performed susceptibility testing. There were 13 different B. fragilis group isolates recovered before tierapy, 14 recovered during therapy, and 14 recovered after therapy. Unfortunately, not all isolates were viable or could be located. However, testing of available isolates revealed the following degrees of resistance: the cefoxitin MIC was >32 g/ml for 2 of 11 pretherapy isolates (18%), 3 of 10 isolates recovered during therapy (30%), and 3 of 9 isolates recovered after therapy (33%). Of these resistant isolates, 50%o were Bacteroides distasonis. In one case, resistant B. distasonis was present before tberapy and persisted. In another case, increasingly resistgnt isolates of the sampe species (B. fragilis) were recovered. In three instances, resistant isolates were species not detected before therapy but only in specimens obtained during or after therapy; these isolates were B. distasonis, B.
fragilis, and B. ovatus.
One or two species of cefoxitin-susceptible, facultative, gram-negative bacilli that were present before therapy were eradicated or decreased (greater than 2 log10) in four of the five patients who could 'be evaluated (patient no. 2 is excluded because the aerobic and facultative isolates from the pretherapy specimen were lost) ( Table 3 ). For patient no.
2, the apparent inconsistency of cefoxitin-resistant Citrobacter freundii present during therapy whereas cefoxitin-susceptible C. freundii was recovered after therapy is explained by the fact that the two isolates had markedly different biochemical characteristics and thus were not the same strain. In three patients, there was ingrowth, after therapy, of cefoxitin-susceptible, facultative, gram-negative bacilli that had not been detected previously (Table 3 ). These were Aeromonas hydrophilaz, C. freundii, Proteus mirabilis, and Proteus sp. All five patients who could be evaluated acquired more than one species of cefoxitin-resistant, facultative or aerobic, gram-negative bacilli during or after therapy (Table 4) .
Three groups of anaerobic bacteria ( that were susceptible by disk diffusion testing were reThe changes noted in the flora of the small number of covered from three patients during therapy. Similarly, MICs patients studied could be shown to be statistically significant of 7 of the 10 isolates of the B. fragilis group recovered only for C. difficile (P = 0.006).
during therapy were <32 pug/ml. A possible explanation is Concentrations of cefoxitin during therapy were 30 and 32 that concentrations of an antimicrobial agent may vary pug/g of feces in two patients.
among different intestinal microenvironments. Another possibility is that certain organisms are merely suppressed but DISCUSSION not eradicated and thus are detected after specimen processing results in dilution and degradation of the drug. Therapy with antimicrobial agents may lead to potentially
The cefoxitin-associated changes in the anaerobic fecal important changes in the intestinal microflora. The altered flora noted in our study are of special interest. The presence gastrointestinal flora may serve as a reservoir of resistant of C. difficile in the feces of five of our six patients suggests and potentially invasive pathogens. Based on our study, that antimicrobial agent-associated acquisition of this organinfection occurring during or after cefoxitin therapy might be ism may be even more common than has been appreciated. ,ug of cefoxitin per ml), may be especially likely to predispose to this acquisition. However, further study is needed to determine the incidence of asymptomatic acquisition of C.
difficile associated with various agents and to investigate factors which might explain colonization by C. difficile without production of disease. The high incidence of acquisition of C. difficile in the present study is remarkable. Because the study involved patients hospitalized on various wards in the hospital and seen over a 3-year period (and who were selected simply because they were to receive cefoxitin and could participate in providing fecal specimens suitable for flora studies at appropriate times), we feel that it is not likely that we observed an outbreak of C. difficile acquisition. C. difficileinduced disease is not uncommon in our institution, and perhaps the extremely high rate of acquisition of this organism is a reflection of a rather unique and appreciable nosocomial reservoir. Thus, our experience may not reflect what should be expected in other locations. Nonetheless, our study suggests that to assess the clinical importance of isolation of C. di:fjicile from a fecal culture, it would be very helpful to know the likelihood of asymptomatic acquisition of C. difficile, not only as associated with various antimicrobial agents but also within an institution.
Altered microecology is thought to be an important antecedent to intestinal ingrowth and disease production by C.
difficile. Previous studies have demonstrated in vitro inhibition of growth of C. difficile by various genera of fecal bacteria (Bacteroides sp., Bifidobacterium sp., and Lactobacillus sp. as well as Pseudomonas sp., Staphylococcus sp., and Streptococcus sp.) (8) . In some of our cefoxitintreated patients, we observed eradication or decrease in counts of some of these genera at the time of ingrowth of C. difficile. Indeed, the inverse possibility that acquisition of C. difficile itself (and, for some patients, the addition of associated colitis) might have contributed directly to alteration of counts of other members of the flora cannot be discounted.
Further investigation of the interactions of C. difficile with specific members of the normal flora seems warranted.
Many of our findings are similar to those reported by Kager and colleagues (5), who studied the effects of cefoxitin prophylaxis on the microflora of patients undergoing colorectal surgery. They observed the proliferation of Streptococcus faecalis and overgrowth of cefoxitin-resistant Enterobacteriaceae family miembers and Pseudomonas sp.
Decreases in counts of anaerobic cocci, Fusobacterium sp., and Bacteroides sp. were also noted. An increase in "cefoxitin-resistant clostridia" occurred in four patients. Unfortunately, these investigators did not indicate specifically whether C. difficile was sought or recovered. It is possible that short courses of prophylaxis led to less predisposition to acquisition of this organism. Alternatively, perhaps this difference is a reflection of different reservoirs of C. difficile.
Our study demonstrates that cefoxitin therapy may be associated with extensive changes in the anaerobic, facultative, and aerobic fecal flora. In practice, the effect of an antimicrobial agent upon fecal flora is seldom considered. For some drugs, the effect is not known or is poorly characterized. As new, broad-spectrum agents are developed, there should be an evaluation of their impact upon intestinal microecology. It is possible that the potential for alteration of the flora from a patient should be a consideration in the selection of optimum antimicrobial therapy.
